Mission Statement, Vision, & Core Values (2026) of Jiangsu Hengrui Medicine Co., Ltd.

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. has grown into a global biopharmaceutical force with products sold in over 40 countries, a pipeline of more than 100 independently developed innovative candidates, and a reputation cemented by seven consecutive years on Pharma Exec's top 50 list; driven by a mission to "promote a healthier life for humankind through advancements in science," Hengrui has poured RMB 50 billion into R&D, translated into the commercialization of 24 new molecular entity drugs and 5 other innovative medicines in China, while reinvesting nearly 30% of revenue into research in 2024 and expanding its global research footprint to 14 R&D centers across China, Japan, the U.S., Australia and Switzerland-anchored by core values of Innovation, Pragmatism, Focus and Diligence and strategic partnerships such as the 2023 Crown Bioscience agreement to discover and commercialize novel therapeutic monoclonal antibodies.

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Intro

• Core therapeutic focuses: oncology; metabolic and cardiovascular diseases; immunological and respiratory diseases; neuroscience.
• Global footprint: products marketed in over 40 countries and regions; 14 R&D centers worldwide.
• Innovation scale: invested over RMB 50 billion in R&D; commercialization of 24 new molecular entity (NME) drugs and 5 other innovative drugs in China.

• Advance human health through science and technology by discovering, developing, and delivering innovative therapies.
• Prioritize patient outcomes, safety, and accessibility of treatments across key disease areas.

• Be a globally respected innovator in pharmaceuticals-transforming breakthroughs into widely accessible medicines.
• Lead in therapeutic innovation with a sustained pipeline of NMEs and differentiated therapies.

• Science-first innovation: continuous, substantial R&D investment (RMB 50+ billion) to drive new molecular entities and first-in-class therapies.
• Patient-centricity: orienting development and commercialization around improved outcomes and broader access.
• Integrity and compliance: adherence to regulatory standards across domestic and international markets.
• Global collaboration: building international R&D centers and partnerships to accelerate development and market entry.

• Pipeline expansion: sustain NME discovery and clinical development across oncology, immunology, cardiometabolic, respiratory, and CNS indications.
• Internationalization: scale regulatory approvals and commercialization beyond China leveraging 14 global R&D centers and distribution networks in 40+ markets.
• Commercial excellence: translate R&D successes into market share and long-term revenue streams while managing payer and access dynamics.
• Talent and infrastructure: invest in scientific talent, advanced R&D platforms, and manufacturing capacity to support global launches.

• Consistently listed among global leaders: Pharma Exec's Top 50 global pharmaceutical companies for seven consecutive years, signaling sustained R&D productivity and market impact.
• Robust innovative output: 24 NMEs and 5 other innovative drugs commercialized in China reflect significant translational capability from lab to market.

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Overview

• Promote a healthier life for humankind through advancements in science - a patient-centric pledge to address unmet medical needs via innovative therapies.
• Substantial, sustained investment in R&D to translate scientific discovery into clinical treatments and improved outcomes for patients worldwide.
• Commercial track record reflecting the mission: 24 new molecular entity (NME) drugs and 5 other innovative drugs approved and commercialized in China.

• To be a global leader in pharmaceutical innovation, delivering safe, effective, and accessible therapies that transform standard of care across major therapeutic areas.
• To expand international reach while maintaining high-quality, science-driven pipelines and manufacturing capabilities.

• Science-led innovation: prioritize rigorous research, clinical evidence, and continuous technological improvement.
• Patient-first ethics: align product development, safety monitoring, and access strategies around patient benefit.
• Integrity and compliance: adhere to global regulatory standards and ethical business conduct.
• Collaboration and talent development: foster partnerships with academic institutions, biotech, and global pharma; invest in human capital.

• High R&D intensity (~30% of revenue in 2024) signals continued reinvestment into pipeline expansion and lifecycle management, with potential long-term revenue growth but near-term margin impact.
• Strong domestic commercialization of NMEs supports recurring revenue streams and provides clinical validation for international expansion.
• Operational priorities-regulatory compliance, manufacturing scale, and global clinical development-are aligned with the stated mission and vision.

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Mission Statement

• Vision emphasis: lead the global pharmaceutical industry by fostering innovation and delivering differentiated therapies to patients worldwide.
• R&D intensity: sustained focus on high-value innovative candidates and platform technologies (oncology, cardiovascular, metabolism, immunology, surgical drugs).
• Globalization: building a footprint through overseas R&D centers and cross-border partnerships to accelerate clinical development and regulatory access.

• Pipeline scale: more than 100 independently developed innovative candidates across discovery, preclinical, and clinical stages, reflecting breadth across modalities (small molecules, biologics, ADCs, cell therapy enablers).
• R&D network: 14 R&D centers globally (China, Japan, United States, Australia, Switzerland) enabling multi-regional clinical development and translational collaboration.
• Partnerships: strategic collaborations to access specialized platforms and CRO/CMO capabilities, exemplified by the 2023 agreement with Crown Bioscience to discover and commercialize novel therapeutic monoclonal antibodies.

• How the vision translates to actions:
  • Invest in early discovery platforms and translational science to increase IND filings and global clinical starts.
  • Scale multi-regional clinical programs to shorten timelines to launch in major markets.
  • Leverage external partnerships (biotech, CROs, academic consortia) to access novel modalities and specialized preclinical models.

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS) - Vision Statement

• Global leadership in innovation-driven therapeutics across oncology, surgical anesthesia, cardiology, and metabolic diseases.
• Patient-centered access: ensure advanced medicines reach broader patient populations domestically and internationally.
• Scientific excellence: build world-class discovery and clinical development capabilities to shorten time-to-patient for breakthrough therapies.

• Innovation - Central to Hengrui's strategy, directing R&D, platform development, and pipeline prioritization to deliver first- or best-in-class medicines.
• Pragmatism - Focus on practical, evidence-based solutions that translate scientific advances into measurable clinical benefit and system-level value.
• Focus - Concentration of resources on strategic therapeutic areas and modality platforms to maximize impact and deepen expertise.
• Diligence - Commitment to rigorous execution, quality assurance, compliance, and continuous improvement across discovery, development, manufacturing, and commercialization.

• Innovation: sustained double-digit R&D intensity has produced a broad pipeline (small molecules, biologics, ADCs, PD-1/PD-L1 programs) and multiple product approvals in China and export registrations in overseas markets.
• Pragmatism: commercialization strategies combine strong hospital relationships, real-world evidence programs, and cost-effectiveness alignment to accelerate uptake.
• Focus: therapeutic concentration-especially oncology-has led to higher clinical success rates and streamlined resource allocation for late-stage trials.
• Diligence: rigorous quality systems and regulatory submissions support manufacturing scale-up and international regulatory filings (e.g., CTAs/MAAs with multiple jurisdictions).

• Collaborations with academic centers and CRO/CMO partnerships to accelerate translational research and clinical development.
• Platform building: biologics engineering, antibody-drug conjugates, and precision medicine capabilities to broaden modality reach.
• Talent and digitalization: recruitment of scientific leaders and deployment of data platforms to shorten development timelines and optimize trial design.